bioSyntagma®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications. Compatible with FFPE and large resections up to an inch in size, the Molecular Fingerprint™ (mPrint) technology has been demonstrated to map tumor microenvironments with custom PCR panels, targeted and total sequencing, and spatial imaging at resolutions ranging from single-cell to complex regions of interest. bioSyntagma’s solution is the first to provide a pathway to diagnostic applications with its proprietary spatial-diagnostic machine learning engine that classifies tissues based on tumor
Takara Bio USA, Inc. and bioSyntagma, Inc. Develop Method for Large-Scale Automated COVID-19 Testing
bioSyntagma, Inc, leveraged our molecular diagnostics expertise, and collaborated with Takara Bio USA, Inc., to develop and validate a new high-throughput method for detecting SARS-CoV-2 (COVID-19). The method employs automation technology and reagents from Takara BUSA to detect viral RNA via real-time PCR and will enable rapid, large-scale testing of the virus during this global pandemic. Click here to learn more. About bioSyntagma bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer
Follow the links to download bioSyntagma’s poster presentation at AACR 2019!
Single biomarkers are no longer sufficient to describe complex biological systems such as the tumor microenvironmentor to predict response to targeted therapies. Advances in molecular analysis have led to the understanding that tumor growth is driven by a network of factors and that spatially resolved, multi-omic measurements are the key to understanding this complex network…
Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards,which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients. “We are delighted by the new sand encouraged that such an innovative group recognizes the value of creating a sustainable healthcare system,” said David Richardson, CEO of bioSyntagma. Katerva scours the globe to identify the most promising, high-impact innovations that will make the world a better place and move society closer